Edited by: Thomas Bieber
Immunological mechanisms of sublingual allergen-specific immunotherapy
Version of Record online: 20 JAN 2011
© 2011 John Wiley & Sons A/S
Volume 66, Issue 6, pages 733–739, June 2011
How to Cite
Novak, N., Bieber, T. and Allam, J.-P. (2011), Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy, 66: 733–739. doi: 10.1111/j.1398-9995.2010.02535.x
- Issue online: 26 APR 2011
- Version of Record online: 20 JAN 2011
- Accepted for publication 6 December 2010
- 1Non-injection routes for immunotherapy of allergic diseases. Clin Allergy Immunol 2004;18:607–623., , .
- 11Tolerogenic T cells, Th1/Th17 cytokines and TLR2/TLR4 expressing dendritic cells predominate the microenvironment within distinct oral mucosal sites. Allergy 2010; 10-9995. [epubmed ahead of print]., , , , , et al.
- 16Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol 2010;126:638–645., , , , , et al.
- 21Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010;40:598–606., , , , , et al.
- 22Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais tablets. Acta Dermatovenerol Alp Panonica Adriat 2010;19:3–10., , , .
- 23Three-year follow-up study of allergen-induced in vitro cytokine and signalling lymphocytic activation molecule mRNA responses in peripheral blood mononuclear cells of allergic rhinitis patients undergoing specific immunotherapy. Int Arch Allergy Immunol 2009;150:370–376., , .
- 27The induced regulatory T cell level, defined as the proportion of IL-10Foxp3(+) cells among CD25(+)CD4(+) leukocytes, is a potential therapeutic biomarker for sublingual immunotherapy: a preliminary report. Int Arch Allergy Immunol 2010;153:378–387., , , , , et al.
- 37Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces Foxp3+CD25+CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions. Scand J Immunol 2006;64:251–259., , , , , .